Usongo Lwesifo Sofuba Esiqhubekayo Esibangela Ubhubhane Oluthule: Inkinga Ye-AMR Iyasondela

Umbiko wakamuva we-#WHO wesifo sofuba wembula iqiniso elicacile: amacala amasha e-TB ayizigidi ezingu-8.2 atholakale ngo-2023—okuyinani eliphakeme kakhulu selokhu kwaqalwa ukuqapha umhlaba wonke ngo-1995. Lokhu kwanda kusuka ku-7.5 million ngo-2022 kubuyisela i-TB njengeumbulali wezifo ezithathelwanayo ohamba phambili, idlula i-COVID-19.

Kodwa-ke, inkinga enkulu nakakhulu ifihla lokhu kuqubuka kabusha:ukumelana namagciwane (i-AMR)I-WHO ibikezela ukuthi ngo-2050, i-AMR ingase ithiukuphila kwabantu abafinyelela ezigidini eziyi-10 ngonyakaemhlabeni wonke, lapho i-TB engazweli emithini (DR-TB) iyimbangela ebaluleke kakhulu. Ngo-2019 kuphela, i-AMR yabulala abantu abayizigidi ezingu-1.3 ngokuqondile—ukwedlula i-HIV/AIDS kanye ne-malaria kuhlangene—futhi manje sekuyikhoimbangela yesithathu ehamba phambili yokufa emhlabeni jikeleleNgaphandle kokungenelela, ukufa okuhlangene okuvela ku-AMR kungafinyelela ku-.izigidi ezingama-39 ngo-2050, kanye nokulahlekelwa kwezomnotho okuphezuluAmaRandi ayizigidigidi eziyi-100.

Kungani Ukuxilongwa Ngesikhathi Kungenakuxoxiswana Ngaso
Ukuphulukiswa kwe-TB kuncike ekutholakaleni kusenesikhathi kanye nezindlela ezifanele zokwelashwa. Kodwa-ke, ukusetshenziswa kabi kwama-antibiotic kuye kwasheshisa i-TB engazweli emithini eminingi (i-MDR-TB), kwaguqula izifo ezingelapheka zaba izinsongo ezibulalayo.

I-TB engazweli emithini ibangela ingxenye eyodwa kwezintathu yokufa kwe-AMR emhlabeni jikelele..

Abantu asebekhulile babhekene nokwanda kokushona kwabantu abane-AMR(kukhuphuke ngo-80% kusukela ngo-1990 phakathi kwabantu abadala).

Ukushintsha kwesimo sezulu kungaseukusabalala kwe-AMR kubi kakhulu ngo-2.4% ngo-2050, okuthinta izifunda ezinemali engenayo ephansi ngokungalingani.

I-WHO ifuna ngokushesha izinto ezintsha ekuxilongweni okusheshayo ukuze kulwiwe nokusetshenziswa kabi kwezifo nokuvala izikhala zokwelapha

 Ikhithi Ye-TB Ezintathu Eqinisekisiwe ye-CE ye-Macro kanye ne-Micro-Test: Amathuluzi Okucacisa Enkathini ye-AMR
Isixazululo sethu sihambisana nesu le-WHO lokulawula i-AMR ngokuvumelaukutholakala ngesikhathi esisodwa kokutheleleka kwe-TB + i-rifampicin (RIF) + ukumelana ne-isoniazid (INH)—kubalulekile ekunciphiseni i-DR-TB.

Izici Eziyinhloko:

Isivinini Nokunemba: Imiphumela emahoreni angu-2–2.5 ngokuhumusha okuzenzakalelayo (kudingeka ukuqeqeshwa okuncane).

Izinhloso Eziphelele:TB: i-gene ye-IS6110

Ukumelana ne-RIF: rpoB (507~533)

Ukumelana ne-INH: InhA, AhpC, katG 315

Ukuzwela Okuphezulu: Ithola amabhaktheriya angaphansi kwe-10/mL (TB) kanye namabhaktheriya angu-150–200/mL ukuze kutholakale izimpawu zokumelana.

I-WHO-Iyahambisana: Ihlangabezana neziqondiso zokuphathwa kwe-DR-TB.

Ukuhambisana Okubanzi: Isebenza nezinhlelo ezinkulu ze-PCR (isb., i-Bio-Rad CFX96, i-SLAN-96P/S).

Kungani Lokhu Kubalulekile:
Ukuhlonza ngokushesha izakhi zofuzo zokumelana kuvimbela ukusetshenziswa okungekuhle kwama-antibiotic, kunciphisa ukudluliselwa,

Ukubizelwa Esenzweni
Ukuhlangana kokubuya kwesifo sofuba kanye ne-AMR kudinga amathuluzi ahlanganisa isivinini ngokunemba. Ikhithi yethu ivala leli gebe—ukuqinisekisa ukuthi ukwelashwa kuqala kahle, okokuqala.

Funda kabanzi:
https://www.mmtest.com/mycobacterium-tuberculosis-nucleic-acid-and-rifampicin%ef%bc%8cisoniazid-resistance-product/
Xhumana:marketing@mmtest.com

#IVD #PCR #AMRCrisis #Ukumelana Nemithi #TB #ENDTB #MDRTB #Ukuxilongwa #GlobalHealth #WHO #MacroMicroTest